The acquisition strengthens BBI’s reagents antibodies portfolio.
The acquisition strengthens BBI’s reagents antibodies portfolio.
Source: BBI

Augmenting antibody services and assay development

Acquisition: BBI gains MBS

BBI Solutions (BBI), immunoassay developer and reagent supplier, acquired Maine Biotechnology Services Inc. (MBS) in July 2017, adding antibody development to the firm’s end to end assay development services. This also strengthens BBI’s reagents antibodies portfolio, providing a wide range of high quality biomarkers for infectious disease.

MBS, based in Portland, Maine (USA), has been a leader in custom antibody development services for over 27 years. The firm’s technical team bring unique hybridoma screening and characterisation protocols to BBI clients. ‘Through this acquisition, BBI Solutions now has the opportunity to partner with IVD development customers earlier in their R&D process, delivering antibodies screened and selected specifically for their end use applications,’ BBI reports.

Customer support will aslo be available through antigen review, cGMP antibody production, purification, and characterisation. ‘Availability of in-house antibody capabilities will be particularly advantageous to lateral flow development customers who can now work with BBI from planning a reagent strategy, through to final diagnostic production,’ the firm adds. ‘Having one comprehensive provider will allow customers to seamlessly identify and prevent antibody performance risks, both during development and over the lifetime of the immunoassay kit manufacturing.’

Products added to BBI Solutions from MBS include antibodies recognising myeloperoxidase, cortisol, osteopontin, PEG, Ig controls, His-tag, norovirus, rotavirus, adenovirus, chikungunya virus, zika virus, and dengue fever.

Go to: www.bbisolutions.com, or visit www.mainebiotechnology.com to read more about BBI antibody development services.


BBI is at MEDICA

Hall 3A. Stand 3AB02-1

12.11.2017

Read all latest stories

Related articles

Photo

Improvement of cardiac care

Rapid myocardial infarction verification

The use of troponin assays to rule in or rule out myocardial infarction (MI) rapidly is critical on several levels. The quick result can reassure the patient that they have not had a heart attack and…

Photo

ECCMID 2015

Curetis launches next-generation pneumonia application

Curetis AG, a developer of next-level molecular diagnostic solutions, announced the successful completion of the clinical and analytical CE performance evaluation of its next-generation Unyvero P55…

Photo

microRNAs hint at cognitive decline

Researchers find warning signs for dementia in the blood

esearchers at the DZNE and the University Medical Center Göttingen (UMG) have identified molecules in the blood that can indicate impending dementia. Their findings, which are presented in the…

Related products

Alsachim, a Shimadzu group company – Dosinaco

Clinical Chemistry

Alsachim, a Shimadzu group company – Dosinaco

Alsachim, a Shimadzu Group Company
ASP Lab Automation – Recapper KapSafe

Sample Processing

ASP Lab Automation – Recapper KapSafe

ASP Lab Automation AG
ASP Lab Automation – Tube Sorter SortPro

Sample Processing

ASP Lab Automation – Tube Sorter SortPro

ASP Lab Automation AG
Beckman Coulter – Access 2 Immunoassay System

Immunoassays

Beckman Coulter – Access 2 Immunoassay System

Beckman Coulter, Inc.
Beckman Coulter – Access Interleukin-6 (IL-6)

Immunoassays

Beckman Coulter – Access Interleukin-6 (IL-6)

Beckman Coulter, Inc.
Subscribe to Newsletter